兔结核模型揭示利福喷丁与利福平在空洞病灶中的药代动力学差异
研究建立能形成类似人类空洞性肺结核病灶的兔结核模型,在给予产生人体等效血浆暴露的利福平或利福喷丁后,测定病灶部位药代动力学与组织药物分布。结果显示利福平穿透干酪样坏死物的系数为1.0,而利福喷丁仅0.25;将病灶部位药代动力学估计值代入临床PK/PD模型后,作用部位暴露与痰培养转阴关系显著(P < 10^-7)。
要点
- 利福喷丁对空洞内干酪样坏死物穿透系数仅0.25,利福平为1.0。
- 两药均能穿透兔肺细胞性病灶及空洞纤维壁(穿透系数≥1)。
- 病灶部位药物暴露与痰培养转阴显著相关(P < 10^-7)。
核心结论
- 利福喷丁对空洞内干酪样坏死物穿透差,部分解释其治疗空洞性结核所需剂量更高的临床现象。
研究设计与样本
- 研究采用兔结核模型,该模型可可靠形成与人类空洞性肺结核特征相似的肺空洞。
- 给予单次或多次利福平或利福喷丁,产生人体等效血浆暴露,不同时间点处死兔子。
- 测定病灶部位药代动力学和组织药物分布,并用PK/PD建模估计药物对不同结核病灶类型的穿透。
主要发现
- 利福平和利福喷丁均穿透兔肺细胞性病灶及空洞纤维壁,穿透系数≥1(相比血浆)。
- 对空洞内干酪样坏死物,利福平穿透系数为1.0,利福喷丁仅0.25。
- 将病灶部位药代动力学估计值代入临床PK/PD模型,作用部位暴露与痰培养转阴关系显著(P < 10^-7)。
关键数值与推荐
- 利福平对干酪样坏死物穿透系数为1.0,利福喷丁为0.25。
- 两药对细胞性病灶和空洞纤维壁穿透系数均≥1(相比血浆)。
- 作用部位暴露与痰培养转阴关系P < 10^-7。
- 两项2期临床试验中,有大空洞的结核患者改善治疗结局所需利福喷丁剂量为无空洞患者的四倍。
临床怎么用
- 提示利福喷丁在空洞性结核患者中可能因病灶穿透不足而疗效受限。
- 支持根据病灶类型(尤其空洞大小)评估利福喷丁剂量需求。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In clinical trials of two rifamycin antibiotics (rifampin and rifapentine) for treating tuberculosis (TB), patients with cavitary lung lesions did not appear to derive benefit from rifapentine. Rifapentine was found not to outperform rifampin, despite a lower minimum inhibitory concentration against Mycobacterium tuberculosis in mouse models of TB. To understand these findings, we have developed a rabbit model of TB that reliably develops lung cavities with features similar to those of patients with pulmonary cavitary TB. After single or multiple doses of rifampin or rifapentine that produced human-equivalent plasma exposures, rabbits were sacrificed at different time points after dosing. We measured site-of-disease drug pharmacokinetics and tissue drug distribution. We used pharmacokinetic-pharmacodynamic (PK/PD) modeling to estimate drug penetration into different types of tubercular lesions. Both drugs penetrated rabbit lung cellular lesions, as well as the fibrotic cavity wall of cavitary lesions (penetration coefficients ≥1 compared to plasma). For the necrotic liquefied material inside cavitary lesions known as caseum (which contains high numbers of bacteria), the penetration coefficient was 1.0 for rifampin but only 0.25 for rifapentine. When estimates of site-of-disease drug PK were substituted into clinical PK/PD models, the relationship between site-of-action exposure and sputum culture conversion was significant (P < 10-7). We propose that poor penetration of rifapentine into lung cavitary lesions explains, in part, why rifapentine doses required to improve treatment outcomes in two phase 2 clinical trials were four times higher in TB patients with large cavities compared to TB patients without cavitary lung disease.
引用
- Rifat D, Prideaux B, Savic RM, et al. Pharmacokinetics of rifapentine and rifampin in a rabbit model of tuberculosis and correlation with clinical trial data. Sci Transl Med. 2018. PMID: 29618565. doi:10.1126/scitranslmed.aai7786
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。